Gross G J, Gharaibeh M
Eur J Pharmacol. 1980 Oct 3;67(1):111-4. doi: 10.1016/0014-2999(80)90016-3.
The actions of molsidomine, a new antianginal agent, on coronary collateral blood flow and myocardial oxygen consumption were studied in anesthetized dogs with acute ligation of the distal third of the left anterior descending coronary artery. Molsidomine (50 and 100 microgram/kg, i.v.) produced a significant decrease in myocardial oxygen consumption, however no change occurred in collateral blood flow. These results suggest that the beneficial actions of molsidomine in myocardial ischemia are primarily due to a decrease in oxygen demand.